Meridian Bioscience Inc. (NASDAQ:VIVO) – Equities researchers at William Blair issued their Q4 2017 EPS estimates for shares of Meridian Bioscience in a note issued to investors on Thursday. William Blair analyst B. Weinstein forecasts that the company will earn $0.16 per share for the quarter. William Blair also issued estimates for Meridian Bioscience’s Q1 2018 earnings at $0.17 EPS, Q2 2018 earnings at $0.22 EPS, Q3 2018 earnings at $0.17 EPS and Q4 2018 earnings at $0.16 EPS.
Meridian Bioscience (NASDAQ:VIVO) last posted its earnings results on Thursday, July 27th. The company reported $0.16 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.16. The business had revenue of $50.14 million for the quarter, compared to analyst estimates of $49.13 million. Meridian Bioscience had a net margin of 10.77% and a return on equity of 16.93%. Meridian Bioscience’s revenue was down 1.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.21 EPS.
Several other equities analysts also recently weighed in on the stock. BidaskClub downgraded shares of Meridian Bioscience from a “buy” rating to a “hold” rating in a report on Thursday, July 6th. Zacks Investment Research downgraded shares of Meridian Bioscience from a “hold” rating to a “sell” rating in a report on Thursday, July 13th. Finally, Canaccord Genuity reaffirmed a “hold” rating and set a $14.00 price target on shares of Meridian Bioscience in a report on Friday, October 13th. Two analysts have rated the stock with a sell rating and five have given a hold rating to the stock. Meridian Bioscience has an average rating of “Hold” and a consensus price target of $14.00.
Meridian Bioscience (NASDAQ VIVO) traded up 0.98% during mid-day trading on Friday, reaching $15.45. 355,616 shares of the company were exchanged. The stock has a market capitalization of $652.04 million, a price-to-earnings ratio of 30.90 and a beta of 0.84. Meridian Bioscience has a one year low of $10.75 and a one year high of $18.90. The stock has a 50 day moving average of $14.36 and a 200-day moving average of $14.38.
In related news, Chairman John A. Kraeutler acquired 7,000 shares of Meridian Bioscience stock in a transaction dated Thursday, August 24th. The shares were purchased at an average price of $13.67 per share, for a total transaction of $95,690.00. Following the completion of the transaction, the chairman now directly owns 345,230 shares in the company, valued at approximately $4,719,294.10. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 2.30% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the company. Advisor Group Inc. raised its position in shares of Meridian Bioscience by 24.9% during the second quarter. Advisor Group Inc. now owns 7,720 shares of the company’s stock valued at $122,000 after buying an additional 1,537 shares during the last quarter. State of Alaska Department of Revenue raised its position in shares of Meridian Bioscience by 77.5% during the second quarter. State of Alaska Department of Revenue now owns 8,273 shares of the company’s stock valued at $130,000 after buying an additional 3,613 shares during the last quarter. BNP Paribas Arbitrage SA raised its position in shares of Meridian Bioscience by 12.5% during the first quarter. BNP Paribas Arbitrage SA now owns 8,633 shares of the company’s stock valued at $119,000 after buying an additional 960 shares during the last quarter. Mason Street Advisors LLC raised its position in shares of Meridian Bioscience by 7.2% during the first quarter. Mason Street Advisors LLC now owns 9,868 shares of the company’s stock valued at $136,000 after buying an additional 667 shares during the last quarter. Finally, Municipal Employees Retirement System of Michigan raised its position in shares of Meridian Bioscience by 3.9% during the second quarter. Municipal Employees Retirement System of Michigan now owns 9,950 shares of the company’s stock valued at $157,000 after buying an additional 370 shares during the last quarter. Hedge funds and other institutional investors own 87.29% of the company’s stock.
About Meridian Bioscience
Meridian Bioscience, Inc is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers.
Receive News & Ratings for Meridian Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience Inc. and related companies with MarketBeat.com's FREE daily email newsletter.